[Two cases of CPT-11 and CDDP chemotherapy for advanced pancreatic cancer]

We report two cases of advanced pancreatic cancer treated with CPT-11 and CDDP as third-line chemotherapy. CPT-11 was administered as an intravenous injection at a dose of 60 mg/m², and CDDP was administered at a dose of 30 mg/m2 biweekly. The patients showed no adverse events greater than grade 2 toxicity, and these adverse events were tolerated. The patients showed partial response and stable disease. These results suggested that this treatment schedule was safe and effective for progressive pancreatic cancer.